# Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma

> **NCT03991962** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yale University** · enrollment: 28 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** mFOLFIRINOX
- **RADIATION:** Stereotactic body radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT03991962
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-24
- **Primary completion:** 2026-08
- **Final completion:** 2027-02
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991962, "Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-05-19 from https://api.ai-analytics.org/clinical/NCT03991962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*